A 6‐month, randomized, double‐blind, placebo‐controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Objective: In patients with Alzheimer's disease (AD) with psychosis or agitation that respond to haloperidol treatment, to evaluate the risk of relapse following discontinuation. Methods: In outpatients with AD with symptoms of psychosis or agitation, responders to 20 weeks of haloperidol (0.5–5 mg daily) were randomized to a 24‐week, double‐blind pilot trial of discontinuation on placebo versus continuation haloperidol. Phase A response criteria were minimum 50% reduction in three target symptoms, and improvement on the Clinical Global Impression‐Change (CGI‐C) score for psychosis/agitation. Phase B relapse criteria required 50% worsening in target symptoms and on the CGI‐C. α = 0.1 was the significance criterion in this pilot study. Results: Of 44 patients, 22 patients responded in Phase A. The sum score of target symptoms, and Brief Psychiatric Rating Scale (BPRS) psychosis and hostile suspiciousness factor scores, decreased in Phase A (p's < 0.001). Extrapyramidal signs increased in Phase A (p < 0.01). Of 22 responders, 21 patients entered Phase B, and 20 had at least one follow‐up visit. Four of 10 patients (40%) on continuation haloperidol relapsed compared to eight of 10 patients on placebo (80%, χ2 = 3.3, p = 0.07). In survival analyses, time to relapse was shorter on placebo than haloperidol (χ2 = 4.1, p = 0.04). Conclusions: Haloperidol open treatment was efficacious, and relapse was greater on placebo than with haloperidol continuation. In patients with AD who have psychosis or agitation and respond to antipsychotic medication, the increased risk of relapse after discontinuation needs to be weighed against the side effects associated with continuing the medication. Copyright © 2010 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671 · cited 4×
“Antipsychotic use has been shown to be associated with increased mortality with an odds ratio of 1.5–1.7 in elderly patients with dementia (Schneider et al., 2005).”
BackgroundInfluentialEffectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., Ismail, M. S., Lebowitz, B. D., Lyketsos, C. G., Ryan, J. M., Stroup, T. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061240 · Cited by 1,206 · cited 4×
“…study were the small sample size Copyright # 2010 John Wiley & Sons, Ltd. and the moderately high dropout rate, though the latter is comparable to that observed in other studies of similar patient populations followed for an extended period of time (Schneider et al., 2006b; Ballard et al., 2009b).”
BackgroundResultInfluentialLyketsos, C. G., Steinberg, M., Tschanz, J. T., Norton, M. C., Steffens, D. C., & Breitner, J. C. S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.708 · Cited by 1,144
Schneider, L. S., Dagerman, K., & Insel, P. S. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000200589.01396.6d · Cited by 903
Ballard, C., Hanney, M. L., Theodoulou, M., Douglas, S., McShane, R., Kossakowski, K., Gill, R., Juszczak, E., Yu, L.-M., & Jacoby, R. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70295-3 · Cited by 567
Sultzer, D. L., Davis, S. M., Tariot, P. N., Dagerman, K. S., Lebowitz, B. D., Lyketsos, C. G., Rosenheck, R. A., Hsiao, J. K., Lieberman, J. A., Schneider, L. S., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07111779 · Cited by 321
Measurement and prediction of functional capacity in Alzheimer's disease
Stern, Y., Hesdorffer, D., Sano, M., & Mayeux, R. (1990) · Neurology · doi:10.1212/wnl.40.1.8 · Cited by 147 · cited 1×
“At baseline, end-Phase A and end-Phase B, cognition was assessed by the MMSE and impairment in activities of daily living was assessed by the modified Blessed Functional Activity Scale (BFAS, Blessed et al., 1968; Stern et al., 1990).”
MethodNonpharmacological intervention for agitation in dementia: A systematic review and meta-analysis
Kong, E.-H., Evans, L. K., & Guevara, J. P. (2009) · Aging & Mental Health · doi:10.1080/13607860902774394 · Cited by 132 · cited 2×
“…for non-pharmacologic behavioral interventions has been inconclusive for most types of interventions (Rovner et al., 1996; Holm et al., 1999; Kong et al., 2009), and the optimal behavioral treatment approach remains uncertain (Ballard Int J Geriatr Psychiatry 2011; 26: 937–943. et al.,…”
BackgroundRaivio, M. M., Laurila, J. V., Strandberg, T. E., Tilvis, R. S., & Pitkälä, K. H. (2007) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e31802d0b00 · Cited by 99 · cited 2×
“, 2009b), though there are other reports showing either no increase (Suh and Shah, 2005; Raivio et al., 2007) or a decrease in mortality risk associated with antipsychotic use in patients with dementia (Simoni-Wastila et al.”
BackgroundResultSimoni-Wastila, L., Ryder, P. T., Qian, J., Zuckerman, I. H., Shaffer, T., & Zhao, L. (2009) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e31819b8936 · Cited by 63 · cited 3×
“However, other evidence suggests no increase, and possibly a decrease, in mortality with antipsychotic use in long term care residents (Simoni-Wastila et al., 2009).”
BackgroundResult
Cited by
Page, A. T., Clifford, R. M., Potter, K., Schwartz, D., & Etherton‐Beer, C. D. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12975 · Cited by 496
Pan, X., Kaminga, A. C., Wen, S. W., Wu, X., Acheampong, K., & Liu, A. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00175 · Cited by 268
New approaches to symptomatic treatments for Alzheimer’s disease
Cummings, J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00424-9 · Cited by 226
Declercq, T., Petrovic, M., Azermai, M., Vander Stichele, R., De Sutter, A. I., van Driel, M. L., & Christiaens, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007726.pub2 · Cited by 206
(2018) · Europe PMC (PubMed Central) · Cited by 196
Metadata
- Authors
- Devanand, D. P., Pelton, G. H., Cunqueiro, K., Sackeim, H. A., & Marder, K.
- Venue
- International Journal of Geriatric Psychiatry
- Publisher
- Wiley
- Published
- 2010-12-28
- Volume
- 26
- Issue
- 9
- Pages
- 937-943
- ISSN
- 0885-6230 (ISSN-L)
- 1099-1166
- OpenAlex
- W1968770674
- Cited by
- 65
- References
- 10
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A 6‐month, randomized, double‐blind, placebo‐controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease. https://app.cochat.ai/papers/10.1002/gps.2630
- The paper
- Devanand, D. P., Pelton, G. H., Cunqueiro, K., Sackeim, H. A., & Marder, K. (2011). A 6‐month, randomized, double‐blind, placebo‐controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease. International Journal of Geriatric Psychiatry. https://doi.org/10.1002/gps.2630
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.